High-level results from the positive registrational Phase II trial DESTINY-Gastric01 showed AstraZeneca (LON:AZN) and Daiichi Sankyo Company, Limited’s Enhertu, achieved a statistically significant and clinically meaningful improvement in objective response rate..

AstraZeneca (LON:AZN) Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma,..

AstraZeneca (LON:AZN) and MSD Inc., Kenilworth, N.J., US (known as Merck & Co., Inc. inside the US and Canada) today announced that a supplemental New Drug Application for Lynparza has..

Following the recommendation from an independent Data Monitoring Committee, AstraZeneca (LON:AZN) has decided to close the Phase III STRENGTH trial for Epanova (omega-3 carboxylic acids) due to its low likelihood..

AstraZeneca (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) has today announced that a supplemental New Drug Application for..

AstraZeneca (LON:AZN) has announced today that Lokelma has been approved in China for the treatment of adult patients with hyperkalaemia. The approval by the National Medical Products Administration (NMPA) was..

AstraZeneca (LON:AZN) has today announced the US Food and Drug Administration has accepted a supplemental New Drug Application and granted Priority Review for Farxiga to reduce the risk of cardiovascular..

AstraZeneca (LON:AZN) and Daiichi Sankyo Company, have today announced that the US Food and Drug Administration has approved Enhertu for the treatment of adult patients with unresectable or metastatic HER2-positive..

AstraZeneca (LON:AZN) today announced that budesonide/glycopyrronium/formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This is the first approval by the National Medical..

AstraZeneca (LON:AZN) today announced that it has agreed to sell the commercial rights to Arimidex and Casodex in a number of European, African and other countries1 to Juvisé Pharmaceuticals. The..

AstraZeneca (LON:AZN) has completed an agreement to divest its commercial rights to Seroquel and Seroquel XR in Europe and Russia to Cheplapharm Arzneimittel GmbH. Financial considerations Under the terms of..

AstraZeneca (LON:AZN) has today announced that it has received marketing authorisation from China’s National Medical Products Administration for Imfinzi for the treatment of patients with unresectable, Stage III non-small cell..

AstraZeneca (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the companies have received marketing authorisation from..

AstraZeneca (LON:AZN) has agreed to sell the commercial rights to Seroquel and Seroquel XR in the US and Canada to Cheplapharm Arzneimittel GmbH. Seroquel and Seroquel XR, used primarily to..

AstraZeneca (LON:AZN) today announced that the US Food and Drug Administration has accepted a supplemental Biologics License Application and granted Priority Review for Imfinzi for the treatment of patients with..

AstraZeneca (LON:AZN) has announced that the European Commission (EC) has approved Qtrilmet modified-release tablets to improve glycaemic control in adults with type-2 diabetes. The approval is based on data from..

AstraZeneca (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) has announced that the US Food and Drug Administration has..

AstraZeneca (LON:AZN) has presented detailed results from the positive Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of moderate to severe systemic lupus erythematosus..

AstraZeneca (LON: AZN) and FibroGen Inc. have presented pooled efficacy and cardiovascular safety analyses from the pivotal Phase III programme assessing roxadustat for the treatment of patients with anaemia from..

AstraZeneca (LON:AZN) has presented detailed results from the Phase III OLYMPUS and ROCKIES trials showing that roxadustat significantly increased haemoglobin levels in non-dialysis-dependent and dialysis-dependent patients with anaemia from chronic..